Spectrum Pharmaceuticals Licenses Belinostat From TopoTarget
Belinostat is also under investigation in a randomized phase 2 trial, as a combination therapy with carboplatin and paclitaxel, for cancer of unknown primary (CUP). Additionally, the NCI
Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.